Replies to post #11517 on Cel Sci Corporation (CVM)

[rwa3848]

All should sell because in December 2016 the FDA challenged CVM to demonstrate that its treatment protocol was not 'futile' . The fact that all subsequent FDA & cel-sci interactions focused only on the Investigator Brochure (after Cel-Sci recognized that incoming data did not require enrollment & survival rate changes to meet stated IND objectives) & not whether the Multikine protocol should be deemed 'futile' clearly is just obfuscation by a regulatory agency (the FDA) not beholden to transparency & its enforcement.